Valneva Austria GmbH, Campus Vienna Biocenter, Vienna, Austria.
Department of Specific Prophylaxis and Tropical Medicine at the Institute of Pathophysiology, Medical University Vienna, Kinderspitalgasse 15, 1090 Vienna, Austria.
Vaccine. 2019 May 1;37(19):2529-2531. doi: 10.1016/j.vaccine.2019.03.030. Epub 2019 Apr 5.
Immunization with the Japanese encephalitis (JE) vaccine IXIARO® results in protective neutralizing antibody levels for one year. Since persistence of protective titer levels beyond one year was unknown, a 5 years follow-up study was conducted. Additionally, data were stratified to compare the persistence of protective neutralizing antibodies against JE in people with or without tick-borne encephalitis (TBE) vaccination. Four weeks after the primary series, the percentage of subjects with PRNT50 titer ≥1:10 in the intent-to-treat population was 99%; the rate after 5 years was 81.6%. By month 24, 36, 48 and 60, the percentages were still 90.7%, 91.7%, 90.1%, 85.9%, respectively in the population who had received TBE vaccine compared to 67.9%, 71.9%, 69.1%, 63.8% in the population who had not. No long-term safety concerns were identified. These data indicate that vaccination with IXIARO® is able to induce protective titers that persist up to 60 months after the primary immunization. Clinical trial registry number NCT00596102.
接种日本脑炎 (JE) 疫苗 IXIARO®可产生一年的保护性中和抗体水平。由于一年后保护性效价水平的持续存在尚不清楚,因此进行了一项 5 年随访研究。此外,对数据进行分层比较,以比较有或无蜱传脑炎 (TBE) 疫苗接种的人群中对 JE 的保护性中和抗体的持续存在情况。在主要系列接种后 4 周,意向治疗人群中 PRNT50 滴度≥1:10 的受试者比例为 99%;5 年后的比率为 81.6%。在接受 TBE 疫苗接种的人群中,在第 24、36、48 和 60 个月时,百分比仍分别为 90.7%、91.7%、90.1%和 85.9%,而在未接种 TBE 疫苗的人群中,百分比分别为 67.9%、71.9%、69.1%和 63.8%。未发现长期安全性问题。这些数据表明,接种 IXIARO®可诱导保护性效价,在初次免疫后可持续长达 60 个月。临床试验注册号 NCT00596102。